B4GALT5

Across TCGA pan-cancer cohorts, B4GALT5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated B4GALT5 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher B4GALT5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated B4GALT5 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, HNSC, and UCEC are the cancer types where B4GALT5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.396	0.770	.008	12	view →
HNSC	OS	Quartile	II,III,IV	0.921	0.388	.006	12	view →
UCEC	DFS	Quartile	All	0.806	1.000	.024	8	view →
CCRCC	OS	Median	All	0.306	1.000	.036	2	view →
LSCC	OS	Quartile	All	0.795	0.955	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

B4GALT5–LUAD (DFS)

Open the LUAD breakdown →